Arbutus Biopharma Corp (NASDAQ: ABUS) has reported E.P.S. of $-0.10 for its third fiscal quarter (ending September 30) versus $-0.12 for the same period a year ago — a decline of -17%. For the latest four quarters through September 30, E.P.S. were $-0.43 compared to $-0.46 a year ago — a decline of -7%.
Recent Price Action
Arbutus Biopharma Corp (NASDAQ: ABUS) stock closed at $3.92 on 11/6/24 after a modest decline of -1.0%. Moreover, above average trading volume at 128% of normal accompanied the decline. The stock has declined -3.0% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ABUS is expected to continue to be Value Creation neutral.
Arbutus Biopharma is currently unrated. The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Arbutus Biopharma has a very low Appreciation Score of 4 but a good Power Rating of 80, resulting in the unrated Value Trend Rating.
Rating Review
The stock is currently unrated.
Be the first to comment